Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.
复制标题
DOI：
10.1038/s41591-021-01464-w
复制
发表时间：
2021-09
期刊：
影响因子：
82.9
通讯作者：
Sester M
中科院分区：
文献类型：
--
作者：
Schmidt T;Klemis V;Schub D;Mihm J;Hielscher F;Marx S;Abu-Omar A;Ziegler L;Guckelmus C;Urschel R;Schneitler S;Becker SL;Gärtner BC;Sester U;Sester M
德国目前建议先用ChAdOx 1 nCoV-19载体疫苗进行异源性初免，然后用信使RNA疫苗（BNT 162 b2或mRNA-1273）加强免疫，但尚无免疫原性和反应原性数据。在这项观察性研究中，我们表明，在健康成年个体（n = 96）中，异源疫苗方案诱导了刺突特异性IgG、中和抗体和刺突特异性CD 4 T细胞，其水平显著高于同源载体疫苗加强后（n = 55），并且在幅度上高于或相当于同源mRNA疫苗方案（n = 62）。此外，异源疫苗接种后的刺突特异性CD 8 T细胞水平显著高于两种同源方案。刺突特异性T细胞主要是多功能的，在所有三种方案中具有很大程度上重叠的产生精氨酸的表型。同源载体方案和异源载体/mRNA组合的接受者在引发载体疫苗接种后报告了更大的反应原性，而异源加强免疫耐受性良好并且与同源mRNA加强免疫相当。总之，异源载体/mRNA加强诱导具有可接受的反应原性特征的强体液和细胞免疫应答。在健康成年人中，与ChAdOx 1 nCov-19加强接种相比，使用mRNA疫苗加强接种（无论用于第一剂的疫苗是什么）耐受性良好，并引发更高水平的尖峰特异性抗体和尖峰特异性T细胞。
Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in Germany, although data on immunogenicity and reactogenicity are not available. In this observational study we show that, in healthy adult individuals (n = 96), the heterologous vaccine regimen induced spike-specific IgG, neutralizing antibodies and spike-specific CD4 T cells, the levels of which which were significantly higher than after homologous vector vaccine boost (n = 55) and higher or comparable in magnitude to homologous mRNA vaccine regimens (n = 62). Moreover, spike-specific CD8 T cell levels after heterologous vaccination were significantly higher than after both homologous regimens. Spike-specific T cells were predominantly polyfunctional with largely overlapping cytokine-producing phenotypes in all three regimens. Recipients of both the homologous vector regimen and the heterologous vector/mRNA combination reported greater reactogenicity following the priming vector vaccination, whereas heterologous boosting was well tolerated and comparable to homologous mRNA boosting. Taken together, heterologous vector/mRNA boosting induces strong humoral and cellular immune responses with acceptable reactogenicity profiles. In healthy adults, booster vaccination with an mRNA vaccine, irrespective of the vaccine used for the first dose, was well tolerated and elicited higher levels of spike-specific antibodies and spike-specific T cells than booster vaccination with ChAdOx1 nCov-19.
登录
查看更多内容
DOI：
10.1016/s0140-6736(20)32661-1
发表时间：
2021-01-09
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Clemens SAC;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Collins AM;Colin-Jones R;Cutland CL;Darton TC;Dheda K;Duncan CJA;Emary KRW;Ewer KJ;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Goodman AL;Green CM;Green CA;Heath PT;Hill C;Hill H;Hirsch I;Hodgson SHC;Izu A;Jackson S;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Lawrie AM;Lelliott A;Libri V;Lillie PJ;Mallory R;Mendes AVA;Milan EP;Minassian AM;McGregor A;Morrison H;Mujadidi YF;Nana A;O'Reilly PJ;Padayachee SD;Pittella A;Plested E;Pollock KM;Ramasamy MN;Rhead S;Schwarzbold AV;Singh N;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Tarrant R;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;Watson MEE;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1056/nejmoa2104840
发表时间：
2021-06-03
期刊：
The New England journal of medicine
影响因子：
--
作者：
Greinacher A;Thiele T;Warkentin TE;Weisser K;Kyrle PA;Eichinger S
通讯作者：
Eichinger S
影响因子：
56.3
作者：
Pollard, Andrew J.;Launay, Odile;Thiebaut, Rodolphe
通讯作者：
Thiebaut, Rodolphe
DOI：
10.1016/s0140-6736(21)01420-3
发表时间：
2021-07-10
期刊：
Lancet (London, England)
影响因子：
--
作者：
Borobia AM;Carcas AJ;Pérez-Olmeda M;Castaño L;Bertran MJ;García-Pérez J;Campins M;Portolés A;González-Pérez M;García Morales MT;Arana-Arri E;Aldea M;Díez-Fuertes F;Fuentes I;Ascaso A;Lora D;Imaz-Ayo N;Barón-Mira LE;Agustí A;Pérez-Ingidua C;Gómez de la Cámara A;Arribas JR;Ochando J;Alcamí J;Belda-Iniesta C;Frías J;CombiVacS Study Group
通讯作者：
CombiVacS Study Group